Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dronabinol buccal - IntelGenx

Next Previous
Drug Profile

Dronabinol buccal - IntelGenx

Alternative Names: CAT 310; Dronabinol AdVersa® Mucoadhesive tablet; Dronabinol buccal - IntelGenx/Tetra Bio Pharma​; Dronabinol XL; INT 0010; INT 0010/2006; INT-0028; INT0028/2011; PPP 002; REDUVO; REDUVO Adversa; Relivar

Latest Information Update: 26 Jun 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cannasat Therapeutics
  • Developer Cynapsus Therapeutics; IntelGenx Corp.; Tetra Bio Pharma
  • Class Antidementias; Antiemetics; Antineoplastics; Appetite stimulants; Cannabinoids; Chromans; Muscle relaxants; Non-opioid analgesics; Small molecules
  • Mechanism of Action Cannabinoid receptor CB1 agonists; Cannabinoid receptor CB2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Cancer pain
  • Suspended Chemotherapy-induced nausea and vomiting
  • No development reported Neuropathic pain

Most Recent Events

  • 19 Jun 2024 Avicanna has patent protection for self-emulsifying drug delivery system (SEDDS) oral cannabinoid compositions and methods for treating neuropathic pain in USA
  • 22 Dec 2022 Tetra Bio-Pharma receives a second Clarification Request (Clarifax) from Health Canada for dronabinol buccal's risk management plan, which is not atypical for a controlled substance drug
  • 16 Nov 2022 Tetra Bio-Pharma receives a Clarification Request (Clarifax) from Health Canada for dronabinol buccal labels

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top